PTCT PTCT
2026-08-20
This is a sample report. Unlock Premium to see the latest reports and the full library.
Unlock with PremiumExecutive summary
PTC Therapeutics has undergone a remarkable financial turnaround: net income swung from -363.3M USD in FY2024 to +682.6M USD in FY2025, with an exceptional Q1 2025 result of +866.6M USD, likely driven by a milestone payment. Operating income followed the same trend, reaching +866.9M USD in FY2025. However, revenue data is not available in the provided series, which limits the ability to calculate margins and fully assess operational efficiency. The balance sheet still shows negative equity (-165.4M USD in Q2 2026), though it improved significantly from -1.098B USD in FY2024. Cash remains strong at 1.05B USD, comfortably covering long-term debt of 535.5M USD (1.96x coverage).
Verdict
En Precio
Stock evolution (2y)
The stock delivered a strong two-year performance, rising from 34.39 USD (Aug 2024) to 71.85 USD (Aug 2026), a total return of +108.9%. During this period, the price ranged from a minimum of 31.42 USD to a maximum of 89.55 USD. The 1-year return stands at +47.1%, indicating continued upward momentum, though the stock has corrected from its late-2025 highs (around 86-89 USD) to the current 72 USD level.
Future catalysts
- ▸Positive progress on renal disease data for ST-920, which could open a new high-value market
- ▸Continued profitability and potential positive equity conversion if operating results remain strong
- ▸Possible reduction of net losses or further milestone payments that could strengthen the balance sheet
Key risks
- ▸Recent insider sales (CEO and CLO) and a 50,000-share resale plan could signal limited upside or create selling pressure
- ▸Equity remains deeply negative, and the increase in long-term debt in Q2 2026 adds financial leverage risk
- ▸Revenue data is unavailable, making it impossible to validate the sustainability of margins; if revenue is low, current profitability may be driven by one-off events
Key financial drivers
The primary driver was the dramatic profitability improvement, with the net result turning positive in FY2025 and remaining positive in Q2 2026 (+83.5M USD). Cash increased from 779.7M USD to 984.6M USD in FY2025 and reached 1.05B USD in Q2 2026. The reduction in accumulated deficit (equity improving from -1.098B to -165.4M USD) also contributed to investor confidence. However, long-term debt increased by ~250M USD in Q2 2026, and insider sales by the CEO and CLO in August 2026, along with a planned 50,000-share resale, may explain some recent price softness.
Informational only: This report is descriptive analysis of public SEC data (Form 4 filings, financial statements) and public market data. It is general, non-personalised information — NOT investment advice within the meaning of Spanish Law 6/2023 nor an investment recommendation under Regulation (EU) 596/2014 (MAR). It does not consider your financial situation, objectives or risk profile. Historical performance does not guarantee future results. Verify data against primary sources and make your own decisions or consult a registered adviser.
Want a free daily digest of insider activity? Subscribe below: